Rising Prevalence of Cardiovascular Diseases in North America Driving Global Cardiovascular Drugs Market Steadily 2017 – 2025

Market Research HUB Market Research HUB

Albany, US, 2017-Nov-23 — /EPR Network/ —It is alarming to know that almost 50% of the deaths are caused due to cardiovascular diseases. The World Health Organization stated that in 2015, about 31% of the deaths across the world were due to cardiovascular diseases (CVD). These CVD related to the heart and blood are also expected to remain on the rise in the coming years. Presently, various companies are indulge in creating a wide range of cardiovascular drugs to treat these diseases. Recently, a study titled “Cardiovascular Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” has been publicized to the online repository of Market Research Hub (MRH), which reveal that growing number of drugs in the pipeline, improving approval rates, and better awareness about CVDs, especially in developing economies, had a major impact on the overall market.

Click here for Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1370921

The study reveal that, between the forecast period of 2017 and 2025, the global market is expected to register a CAGR of 1.5% to reach a valuation of US$162.96 bn by the end of 2025. Increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market. Presently, increasing investments in research and development and growing number of medical trials are expected to have to intensify the competition among key players in the global market.

Cardiovascular drugs are defined as medication used as a means to control or to prevent certain forms of heart disease. Various drugs are available and are under development for treating cardiovascular diseases based on various indications, such as arrhythmia, myocardial infarction, atherosclerosis, etc. Changing lifestyles, poor dietary intake, and genetic predisposition are expected to increase the demand for cardiovascular drugs in the near future. Furthermore, conditions such as diabetes, high cholesterol, depression, and obesity have also played a significant role in spiking the demand for cardiovascular drugs all over the world.

This new research report begins with an executive summary which includes market definition and taxonomy. Besides, the report takes a close look on the segmentation of global market for cardiovascular drugs. The study broadly evaluates the market on the basis of drug class, distribution channel and by region. The regional outlook of the report highlights prime regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. On the basis of drug class, the market is segmented into anti hyperlipidemics, anti hypertensives, anti arrhythmatics, anticoagulants, antifibrinolytics and other. Major distribution channel in this market include retail pharmacies, hospital pharmacies, and online pharmacies.

Browse Full Report with TOC@ https://www.marketresearchhub.com/report/cardiovascular-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html

Presently, North America is projected to stay ahead of others in the overall market during the forecast period, owing to high prevalence of cardiovascular diseases. Apart from that, Asia Pacific is also estimated to make significant impact on global market.

By gauging all the key parameters, a complete view of the market along with its competitive dynamics has been provided in the report. This section of the report allow the reader to understand the competitive landscape of the market including, regional presence, revenue, product portfolio and major developments. Significant companies profiled in the report include Bayer AG, AstraZeneca plc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceutical Company Limited.

Enquire about this Report@ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1370921

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News at – https://www.industrynewsanalysis.com/

 

 

 

Matched content

Editor’s pick

Express Press Release Distribution